<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the in-vivo preclinical antitumor activity of <z:chebi fb="0" ids="17183">sanguinarine</z:chebi> in a rat syngeneic model of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The effects of <z:chebi fb="0" ids="17183">sanguinarine</z:chebi> on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DHD</z:e>/K12/TRb colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells were first evaluated in vitro by means of ³H-<z:chebi fb="0" ids="17748">thymidine</z:chebi> incorporation, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay, and terminal transferase <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick end labeling (TUNEL) microscopy </plain></SENT>
<SENT sid="2" pm="."><plain>For the in-vivo studies, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DHD</z:e>/K12/TRb cells (1.5 × 10⁶ cells/0.3 ml of <z:mp ids='MP_0001924'>sterile</z:mp> saline/animal) were injected subcutaneously in syngeneic BDIX rats, which were chronically treated with <z:chebi fb="0" ids="17183">sanguinarine</z:chebi> (5 mg/kg/day per os) or control diluent </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">Tumor growth</z:e>, body weight, hematologic, and clinical chemistry measurements were monitored in individual animals at defined time intervals </plain></SENT>
<SENT sid="4" pm="."><plain>After killing, subcutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were explanted from experimental animals for histopathological examination </plain></SENT>
<SENT sid="5" pm="."><plain>In vitro, micromolar concentrations of <z:chebi fb="0" ids="17183">sanguinarine</z:chebi> inhibited dose-dependently <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DHD</z:e>/K12/TRb cell proliferation and metabolism and induced cell <z:hpo ids='HP_0011420'>death</z:hpo> by <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo, oral administration of <z:chebi fb="0" ids="17183">sanguinarine</z:chebi> induced a significant inhibition of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> (P&lt;0.01 vs. untreated controls), in the absence of any toxic or side effects </plain></SENT>
<SENT sid="7" pm="."><plain>Marked <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and reduced peritumoral vascularization were observed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from <z:chebi fb="0" ids="17183">sanguinarine</z:chebi>-treated rats as compared with the controls </plain></SENT>
<SENT sid="8" pm="."><plain>Additional basic studies are needed to fully characterize the mechanism/s underlying the inhibitory effects of <z:chebi fb="0" ids="17183">sanguinarine</z:chebi> on <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> as well as the pharmacological and safety profile of this drug in <z:e sem="disease" ids="C0027659" disease_type="Neoplastic Process;Experimental Model of Disease" abbrv="">experimental tumor</z:e> models </plain></SENT>
<SENT sid="9" pm="."><plain>Overall, findings from this study suggest that <z:chebi fb="0" ids="17183">sanguinarine</z:chebi> is a likely candidate for further evaluation in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
</text></document>